US regulatory status: approved.
pharma · Not applicable, Healthy Volunteers · advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)
mAbxience
Mabxience Research SL
mAbxience drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
madrid, ES HQ
2009 Founded
1,194 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- madrid, ES
- Founded
- 2009
- Employees
- 1,194
- Programs
- 5
- Drugs
- 10
- Patents
- 0
mAbxience pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
mAbxience drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to mAbxience in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
etanercept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to mAbxience in public FDA and regional records.
-
Development asset linked to mAbxience in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to mAbxience in public FDA and regional records.
-
Development asset linked to mAbxience in public FDA and regional records.